drugset

drugset / Trial / NCT03105219

IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease

NCT03105219 ↗

Phase 3 Withdrawn Nanjing First Hospital, Nanjing Medical University

RandomizedParallel-groupSingle-blindTreatment

Summary

To explore the efficacy of Ivabradine for the treatment of microalbuminuria in patients with type 2 diabetes and coronary heart disease.

Timeline

Start: 2017-07-01
Primary completion: 2021-05-30
Completion: 2021-05-30

Outcome

Outcome not reported

Stopped (Business): “Shortfall in funding”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ivabradine	Small molecule	7.5 mg	—

Indications